Church & Dwight Co., Inc. (CHD) Stock Price Today
Aura AI Summary
Key Stats
- $24.01BMarket Cap
- -Volume
- Consumer StaplesSector
- $105.2652W High
- $81.6052W Low
- -Typical Hold Time
- $26.02BEnterprise Value
- 1.21%Div Yield
- -Trading Activity
Track Church & Dwight Co., Inc. (CHD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Church & Dwight Co., Inc. has traded between a low of $81.6 and a high of $105.26, highlighting its annual price range. Buy and sell Church & Dwight Co., Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Most Recent News
Goldman Sachs downgrades AMD to Sell despite record Q2 revenue and AI growth.
Goldman Sachs downgraded Advanced Micro Devices (AMD) to a Sell rating despite the company reporting record Q2 revenue of $11.54 billion, driven largely by its Data Center segment which accounts for 58% of sales. AMD projects strong Q3 revenue of $13...
Stocks fall sharply amid fraud probe and mixed earnings, with Cellebrite down 29%.
Several stocks dropped significantly today due to various company-specific issues. Cellebrite DI Ltd. plunged 29.18% following a securities fraud investigation, while Securitize Corp. fell 27.48% despite a major NYSE listing milestone. Liftoff Mobile...
Altimmune CEO buys shares, signaling confidence amid strong Q2 results and MASH drug progress.
Altimmune's CEO recently purchased 15,000 shares at $2.95 each, showing strong leadership confidence in the company's future. The biopharmaceutical firm reported a better-than-expected Q2 loss of $0.12 per share and holds $519 million in cash, securi...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.